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Background: Histone citrullination by PAD4 regulates tumor suppressor gene expression.
Results: The novel PAD inhibitor YW3-56 inhibits cancerous growth by perturbing autophagy and regulating the SESN2-
mTORC1 signaling axis.
Conclusion: YW3-56 regulates the SESN2-mTORC1 autophagy pathway as one of its anticancer mechanisms.
Significance:This study identifies a novel function of PAD4 in the autophagy pathway and developed potent PAD inhibitors for
future cancer research.
Tumor suppressor genes are frequently silenced in cancer
cells by enzymes catalyzing epigenetic histone modifications.
The peptidylarginine deiminase family member PAD4 (also
calledPADI4) ismarkedly overexpressed in amajority of human
cancers, suggesting that PAD4 is a putative target for cancer
treatment. Here, we have generated novel PAD inhibitors with
low micromolar IC50 in PAD activity and cancer cell growth
inhibition. The lead compound YW3-56 alters the expression of
genes controlling the cell cycle and cell death, including SESN2
that encodes an upstream inhibitor of the mammalian target of
rapamycin complex 1 (mTORC1) signaling pathway. Guided by
the gene expression profile analyses with YW3-56, we found
that PAD4 functions as a corepressor of p53 to regulate SESN2
expression by histone citrullination in cancer cells. Consistent
with the mTORC1 inhibition by SESN2, the phosphorylation of
its substrates including p70S6 kinase (p70S6K) and 4E-BP1 was
decreased. Furthermore, macroautophagy is perturbed after
YW3-56 treatment in cancer cells. In a mouse xenograft model,
YW3-56 demonstrates cancer growth inhibition activity with
little if any detectable adverse effect to vital organs, whereas a
combination of PAD4 and histone deacetylase inhibitors fur-
ther decreases tumor growth. Taken together, our work found
that PAD4 regulates the mTORC1 signaling pathway and that
PAD inhibitors are potential anticancer reagents that activate
tumor suppressor gene expression alone or in combinationwith
histone deacetylase inhibitors.
In eukaryotic cells, covalent histone modifications play
important roles in regulating gene expression during normal
development and in disease etiology (1, 2). Notably, aberrant
silencing of tumor suppressor genes by epigeneticmodifiers has
been recognized as an early onset event during tumorigenesis
(3–5). Within the last several decades, small molecule inhibi-
tors against DNA methyltransferases and histone deacetylases
have been developed as effective reagents to activate tumor
suppressor gene expression in cancer chemotherapy (6). Com-
pounds against novel epigenetic targets, such as Dot1L and
Brd4, have been recently reported to effectively inhibit cancer-
ous growth in mouse models (7–9). As such, a new battlefront
for cancer treatment is emerging from studies of the epigenetic
mechanisms underlying tumorigenesis, which bears promise
for the identification of new drug targets and the development
of additional pharmacological reagents.
Peptidylarginine deiminases (PADs)4 are a family of enzymes
that can convert protein Arg residues to citrulline in a calcium-
and sulfhydryl group-dependent manner. The PAD protein
family in human and mouse contains five members, including
PAD1–4 and PAD6, that show tissue and substrate specificity
(10, 11). PAD1 is mainly expressed in the epidermal keratino-
cytes (57). PAD6 (also called ePAD) is a protein uniquely
expressed in eggs and regulates the early stage of embryonic
development, but it misses a conserved cysteine residue at the
active center of all other PAD enzymes (12, 13). PAD2 is widely
expressed in many tissues, including muscle, brain, and mam-
mary gland, and is found to citrullinatemyelin basic protein and
actin (10, 11, 14). PAD4 is the only PAD family member con-
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strates including histones (e.g.H3, H2A, and H4), p300/CREB-
binding protein (CBP), nucleophosmin, ING4, and nuclear
laminC to exert various functions (15–19). Genome-wide asso-
ciation and pathology studies have implicated PAD4 in the eti-
ology of rheumatoid arthritis and cancers in human patients
(20–23). We previously found that PAD4 functions as a core-
pressor of p53 and cooperates with a histone deacetylase
HDAC2 to repress the expression of tumor suppressor genes
(e.g. p21/CDKN1A and GADD45) (24, 25). Moreover, PAD4
was recently reported to cooperate with Elk-1 to facilitate c-fos
expression. As such, PAD4 can positively and negatively regu-
late transcription in a promoter context-dependent manner
(14, 24).
The tumor suppressor p53 protein functions as a central hub
and key transcription factor of many cellular signaling path-
ways (26). In response to DNA damage, starvation, and stress
signals, p53 regulates the expression of many genes that in turn
relay the upstream signal to determine whether a cell under-
goes cell cycle arrest, apoptosis, autophagy, etc. (27–30).
Genome-wide mapping efforts have identified several hundred
potential p53 target genes (31); many of these p53 target genes
are effector proteins or proteins that regulate p53 functions in
various positive and negative feedback loops (32). Sestrin 2
(SESN2) is a recently identified p53 target gene that regulates
aging and induces autophagy by inhibiting themTORC1 signal-
ing pathway via the AMP-activated protein kinase (AMPK) and
TSC1/2 signal cascade (33, 34). Interestingly, PAD4 was also
recently identified as a p53 target gene, suggesting that PAD4 is
a component of the intricate p53 signaling network (19, 35),
suggesting that PAD4 likely regulates p53 function via a nega-
tive feedback loop.
Macroautophagy (hereafter referred as autophagy) is a cata-
bolic cellular process wherein a large number of cytoplasmic
components and organelles are engulfed by a membrane struc-
ture termed the phagophore to form autophagosomes, which in
turn fuse with lysosomes to form autophagolysosomes for bulk
degradation to remove damaged cellular organelles or regener-
ate metabolites during the cellular response to starvation (36–
38). Autophagy is an important cellular process for organism
health, and its deregulation has been linked with the progres-
sion ofmany human diseases, including neurodegenerative dis-
orders and cancers (36, 39). Many autophagy regulatory factors
are evolutionarily conserved from yeast to human, including
the mammalian target of rapamycin (mTOR) Ser/Thr kinase-
containing mTORC1 protein complex, which senses growth
factors and nutrient abundance to control the rate of protein
synthesis and the flux of autophagy (38, 40). The Yin-Yang bal-
ance of autophagy flux is key to maintaining the homeostasis
between cell survival and cell death. The metabolites recycled
through autophagy can sustain cell survival and contribute to
chemotherapy resistance (41). On the other hand, under cir-
cumstances of excessive degradation of cellular components,
autophagy can result in cell death (42). Therefore, both induc-
ers and inhibitors of autophagy are of potential value for cancer
treatment by regulating the autophagy flux rate.
Under physiological conditions, PAD4 ismainly expressed in
peripheral blood neutrophils. We have previously found that
PAD4 plays an antibacterial innate immune function through
regulating the formation of neutrophil extracellular traps (43).
On the other hand, PAD4 is markedly overexpressed in a
majority of cancers of various tissue origins in pathology studies
with a large cohort of human patient samples (21), suggesting
that PAD4 may play a role in tumorigenesis. Currently, it
remains unknown whether PAD4 can be pharmacologically
targeted for cancer treatment. Cl-amidine is a benzoyl-argin-
ine-derived and mechanism-based pan PAD inhibitor that
shows inhibitory effects to several PAD family members (44,
45). However, this compound causes cancer cell growth inhibi-
tion at 150–200 M concentration in cultured cells (24, 25).
The relatively low potency of Cl-amidine limits its preclinical
exploration in cancer study and treatment. We have tested the
idea that efficient smallmolecule PAD inhibitors can epigeneti-
cally activate tumor suppressor genes, thereby offering new
avenues for cancer research and treatment. Our results showed
that the lead compound YW3-56 activates a cohort of p53 tar-
get genes, including SESN2, which in turn inhibits the
mTORC1 signaling pathway, thereby perturbing autophagy
and inhibiting cancerous cell growth.
EXPERIMENTAL PROCEDURES
Chemical Synthesis and Colorimetric Assays of PAD4
Inhibitors—The method for chemical synthesis of novel PAD4
inhibitors was done largely following a method described pre-
viously (44). The colorimetric PAD4 assay method is described
in detail in the supplemental material.
Cell Culture and Treatment with Compounds and siRNA—
Human osteosarcoma U2OS and mouse sarcoma S-180 cells
were purchased from ATCC and cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serumand1%penicillin-streptomycin in a 5%CO2 incu-
bator. Early passage cells were used to minimize passage devi-
ations. U2OS p53-shRNA and U2OS Ctrl-shRNA cells were
generated essentially as described previously (25). Concentra-
tions and duration of YW3-56 treatment were performed as
specified in the figure legends and text of the current study. For
the starvation assay, U2OS cells were first cultured in serum-
free DMEM for 16 h and then in 10% fetal bovine serum, then
different concentrations of YW3-56 were added back, and cells
were further incubated for 8 h before additional analyses.
SESN2 siRNA (Santa Cruz Biotechnology) and GFP siRNA
(Dharmacon Inc.) were transfected into U2OS cells using the
X-tremeGENE siRNA transfection reagents (Roche Applied
Science). Cells were incubated in the presence of the siRNA for
48 h before addingYW3-56 and further incubated for 8 h before
analyses.
MTT and Flow Cytometry Assays—Details of MTT and flow
cytometry assays can be found in the supplemental material.
Transmission Electron Microscopy and Phase Contrast
Microscopy—U2OS Cells were treated with 6 M YW3-56 for
24 h and fixed in 2% glutaraldehyde in 0.1 M phosphate buffer,
pH 7.4. Transmission electron microscopy analyses of U2OS
cell morphology were performed using the service of the Penn
State ElectronMicroscopy Facility. AVistaVision invertmicro-
scope (VWR International, LLC) equippedwith a SPOT Insight
digital camera (Diagnostic Instruments, Inc.) and a 10 phase
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contrast lens were used to analyze cell growth and morphology
in phase contrast microscopy analyses.
RNA Extraction, Microarray, Reverse Transcription, and
Quantitative PCR—Details of these methods can be found in
the supplemental material.
Western Blot and Fluorescent Imaging—Western blot and
immunostaining were performed essentially as described pre-
viously (25). Antibodies used in Western blot were anti-p53
(Sigma, BP53-12), anti-PAD4 (custom-made), anti-H3Cit
(Abcam, ab5103), anti-H3 (Abcam, ab1791), anti-p21 (Sigma,
P1484), anti-PUMA (Calbiochem, PC686), anti-SESN2
(Abcam, ab57810), anti-p70S6K (Cell Signaling, 9202), anti-
p70S6K-pT389 (Cell Signaling, 9205), anti-LC3B (Cell Signal-
ing, 2775), anti-p62/SQSTM1 (Bethyl Laboratories, A302-
855A), and anti--actin (Sigma, A1978) at the appropriate
dilutions. Anti-LC3B antibody (Cell Signaling, 2775) was used
for immunostaining. DNA was stained by the DNA dye
Hoechst. For subcellular localization of YW3-56, U2OS cells
were treated with YW3-56 for 12 h and then fixed in 3.7% para-
formaldehyde in PBS buffer containing 0.1% Triton X-100 and
0.2% Nonidet P-40, pH 7.4. Nuclear DNA was visualized by
TOPRO3 staining and captured using an Olympus BX61
microscope at excitation 647 nm/emission 665 nm. Images of
YW3-56 subcellular distribution were captured at excitation
359 nm/emission 461 nm.
Chromatin Immunoprecipitation (ChIP) Assay—ChIP ex-
periments were carried out essentially as described previously
(14). Antibodies used in ChIP were: anti-p53 (Sigma, BP53-12),
anti-PAD4 (custom-made), anti-H3Cit (Abcam, ab5103), and
anti-H3R17Me (Abcam, ab8284). Primers used in quantitative
ChIP-qPCR for 733 are listed in supplemental Table S2.
Other primers are available upon request.
In Vivo Antitumor Assay—S-180 ascites tumor cells were
used to form solid tumors after subcutaneous injection essen-
tially as described previously (46). More details are available in
the supplemental material. All animal experiments were
approved by the Institutional Animal Care and Use Committee
of Capital Medical University and performed by accepted vet-
erinary standards.
RESULTS
Novel PAD Inhibitors with Increased Ability to Inhibit PAD4
and Cancer Cell Growth—To develop more potent inhibitors
for PAD4 inhibition and cancer cell killing, we carried out an
extensive structure-and-activity relationship study based on
the Cl-amidine blueprint (Fig. 1A). TheN and C of the orni-
thine backbone were engineered with different structural
motifs or tetheredwithin a ring scaffold via the standard amide-
and ester-coupling chemistry to generate 23 new compounds in
four synthesis, evaluation, and redesign cycles (supplemental
Fig. S1). Cl-amidine is a very hydroscopic compound, which
readily dissolves in water-based solutions and likely has low cell
membrane permeation ability. Therefore, one of the design
schemeswas to optimize the hydrophobicity and bioavailability
of the new compounds. The 23 compoundswere first used at 20
M tomeasure their cell-killing efficacy in osteosarcomaU2OS
cells by MTT assays (supplemental Fig. S2). Several potent
inhibitors (e.g. YW3-56, YW4-03, and YW4-15) were selected
to measure their IC50 in cell killing by MTT assays and PAD4
inhibition by a colorimetric method (47) (supplemental Fig.
S3). Inhibitors with low micromolar IC50 values, including
YW4-03 and YW3-56, were successfully developed (Fig. 1B).
When compared with Cl-amidine, YW3-56 showed 60-
fold increase in cell growth inhibition efficacy (IC50 about 2.5
M) but only 5-fold increase in PAD4 inhibition (IC50 about
1–5 M) (Fig. 1B). We postulated that the dimethyl-amide-
naphthalene moiety at theN position and a phenyl ring at the
C position increase the hydrophobicity of YW3-56, thereby
enhancing its membrane permeability and cancer cell killing.
To test this idea, flow cytometry analyses were performed to
evaluate cellular uptake of YW3-56 using the intrinsic fluores-
cent signal generated by the naphthalene moiety in YW3-56
(Fig. 1C). Fluorescent signals were greatly increased in all cells
after YW3-56 treatment when compared with untreated cells
(Fig. 1C). To further test the importance of membrane perme-
ation in cell killing, a bulky and hydrophilic biotin moiety was
added on the para position of the C benzyl ring of YW3-56 to
generate YW4-15. This biotinmoiety greatly decreased the cel-
lular uptake of YW4-15 in flow cytometry analyses (Fig. 1C). As
a consequence of poor membrane penetration, although
YW4-15 has a PAD4 inhibition efficacy similar to YW3-56, its
cancer cell killing ability was greatly decreased when compared
with YW3-56 (Fig. 1B). Taken together, the above results indi-
cate that YW3-56 has an improved efficacy in PAD4 inhibition
and cell membrane penetration and thereby kills cancer cells
with high efficacy.
Based on the above results, we chose YW3-56 as the lead
compound for further detailed biological analyses. Taking
advantage of the fluorescent naphthalene moiety, we analyzed
the subcellular distribution of YW3-56 and found that it is
mainly concentrated in the nucleus, with a certain degree of
enrichment in the nucleolus to form punctate structures (Fig.
2A). Because PAD4 is a nuclear protein, the nuclear localization
of YW3-56 indicates that it is in the same subcellular compart-
ment as PAD4. The nucleolar localization of YW3-56 is notable
given that nucleophosmin, an abundant protein in the nucleo-
lus, is a known substrate of PAD4 (35, 48). Furthermore, we
analyzed the dose-dependent effects of YW3-56 on cell mor-
phology and growth. At 2–4 M concentrations, YW3-56 dis-
played mainly cytostatic effects by slowing cell division,
whereas at higher concentrations, it exerted cytotoxic effects by
altering cell morphology and killing cells (supplemental Fig.
S4). Recently, PAD4 and to a lesser extent PAD2, but not PAD3,
were reported to citrullinate histoneH3 (11). Given our interest
in understanding histone citrullination in gene regulation, we
next evaluated the target specificity of YW3-56 to PAD4 and
PAD2 using histone H3 as a substrate. Consistent with the pre-
vious study (11), PAD2 had aweaker activity toward histoneH3
when compared with PAD4 (Fig. 2B). On the other hand, using
histone H3 as a substrate, the IC50 of YW3-56 in PAD4 inhibi-
tion is about 1–2 M, whereas its IC50 in PAD2 inhibition is
about 0.5–1M (Fig. 2C). Due to its inhibitory activity to PAD2,
YW3-56 is referred to as a PAD inhibitor hereafter.
YW3-56 Induces p53 Target Genes and Regulators of
mTORC1—To analyze the molecular mechanisms by which
YW3-56 induces cancer growth inhibition, we performed
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microarray analyses usingAffymetrixmicroarray chips. Using a
1.5-fold change as the cutoff (n 3, false discovery rate0.05),
843 genes were induced, whereas 646 genes were repressed
after YW3-56 treatment in U2OS cells. Gene ontology analyses
found that the cell cycle, nucleosome assembly, gene regula-
tion, and cell death pathway genes were significantly enriched
(Fig. 3A). Within the group of genes of the nucleosome assem-
bly pathway, the expression of multiple histone genes was
decreased by severalfold (supplemental Fig. S5, A and B). The
decreased histone gene expression was further analyzed using
reverse transcription quantitative PCR (RT-qPCR) to corrobo-
rate the microarray results (supplemental Fig. S5C). Both
microarray andRT-qPCR assays detected a significant decrease
of histone genes, suggesting that YW3-56 can impact on the cell
cycle progression by inhibiting histone gene expression via
mechanisms yet to be characterized in future research. More-
FIGURE 1. Synthesis and characterization of more potent PAD4 inhibitors. A, structures of PAD4 inhibitors, including the prototype inhibitor Cl-amidine
(upper left panel), the generic structure for medicinal chemistry modification (upper middle panel), the new compound YW4-03 (upper right panel), the lead
compound YW3-56, and its biotin-conjugated form YW4-15. YW3-56 and YW4-15 are intrinsically fluorescent molecules because of the dimethyl-amide-
naphthalene moiety. B, tabulation of the IC50 values of cell growth and PAD4 inhibition by several representative inhibitors. IC50 for PAD4 inhibition was
measured using colorimetric assays. IC50 for cell growth inhibition was measured by MTT assays in the above three independent experiments. C, flow cytometry
assays to measure the accumulation of YW3-56 and its biotin-conjugated form YW4-15 after 10 M of compound treatment for 12 h (a representative result of
three repeats is shown).
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over, because PAD4 regulates the expression of p53 target
genes (24, 25), we compared our microarray gene list with the
122 direct p53 target genes reported previously (31). 14 genes
identified in themicroarray analyses overlapwith the p53 target
genes, representing a significant enrichment of p53 genes (14/
122, p  0.01) (Fig. 3A). To show the consistency of the three
independent microarray experiments, heat maps of 356 genes
showing an average of 2-fold increase and 227 genes showing
an average2-fold decrease are presented (Fig. 3B). In contrast
to the primary decrease in histone gene expression, genes of the
p53 pathway were mainly up-regulated after YW3-56 treat-
ment (supplemental Table S1). Notably, two upstream regula-
tors of the mTOR signaling pathway, SESN2 and DDIT4 (also
called REDD1), were induced 6.1- and 4.2-fold, respectively,
after YW3-56 treatment (supplemental Table S1). Both SESN2
and DDIT4 repress the mTORC1 kinase activity through the
TSC1/2 signaling axis (33, 49), suggesting that YW3-56 treat-
ment may impact on the SESN2/DDIT4 3 TSC1/TSC2 3
mTORC1 signaling axis.
To assess the importance of p53 in YW3-56-mediated cell
growth inhibition, we performed MTT assays in U2OS cells
with orwithout p53 depletion by shRNA.Depletion of p53 con-
stantly attenuated the cell growth inhibition efficacy of YW3-56
(supplemental Fig. S6A, * indicates p  0.02), suggesting that
the relative abundance of p53 plays a role in YW3-56-induced
cell killing in U2OS cells. RT-qPCR analyses showed a decrease
in p53 mRNA after the p53 shRNA treatment (Fig. 4A). The
basal level of SESN2, p21/CDKN1A, and PUMA expression was
decreased by p53 depletion (Fig. 4A and supplemental Fig. S6B).
In contrast, the basal level expression ofDRAM (damage-regu-
lated autophagy modulator), AMPK, PIG3, and BAX was not
affected by p53 depletion (Fig. 4A and supplemental Fig. S6B).
After YW3-56 treatment, the expression of SESN2, p21/
CDKN1A, and PUMAwas strongly induced in control shRNA-
treated U2OS cells but induced to a relatively lower amount in
p53-depleted cells (Fig. 4A and supplemental Fig. S6B). The
expression of mTOR regulator SESN2 but not AMPK was
increased after YW3-56 treatment in a p53-dependentmanner,
suggesting that YW3-56 specifically activates a subset ofmTOR
regulatory genes (Fig. 4A). Moreover, the relatively less potent
inhibitors YW3-88 and BL1-07 induced the expression of p53
target genes, including SESN2, at higher concentrations, sug-
gesting thatmultiple PAD inhibitors can exert similar effects on
gene activation in U2OS cells (supplemental Fig. S7).
PAD4 Serves as a Corepressor of p53 to Directly Regulate
SESN2 Expression—To analyze whether YW3-56 primarily tar-
gets PAD4 to exert its effects on histone citrullination and
SESN2 expression, we treated U2OS cells with YW3-56 and
PAD4 siRNA. Both YW3-56 treatment and siRNA depletion of
PAD4 activated SESN2 expression and decreased histone H3
citrullination (Fig. 4B), suggesting that PAD4 plays a direct role
in regulating SESN2 expression. Moreover, depletion of PAD4
sensitizes cell responses to YW3-56 treatment, showing a fur-
ther decrease in histone H3 citrullination and increase in
SESN2 expression (Fig. 4B). Although YW3-56 was found to
inhibit PAD2 and PAD4, the histone H3 citrullination activity
of PAD2 is much weaker in vitro (Fig. 2C), and PAD2 preferen-
tially localizes to the cytoplasm (50). The above results indicate
that PAD4 is the main enzyme responsible for histone H3 cit-
rullination and a main target of YW3-56 in regulating the
SESN2 expression. On the other hand, it remains possible that
YW3-56 impacts on PAD2 in other aspects of its anticancer
activity.
Although SESN2was reported as a p53 target gene, the direct
evidence for p53 binding on a specific region of the SESN2
promoter is not available according to our knowledge. To map
p53 binding site(s) at the SESN2 gene, we performed ChIP
experiments using a set of primers spanning regions of the
SESN2 gene with putative p53 binding consensus sites pre-
dicted by the PROMOprogram (Fig. 4C). The binding of p53 to
the 733 position of SESN2 was increased 8-fold after UV
irradiation treatment in U2OS cells (Fig. 4D), suggesting that
this region contains putative p53 binding sites. Moreover, p53
binding at the 733 position of SESN2 was increased 4-fold
with a concomitant increase of histone H3 Arg-17 methylation
(H3R17Me) after YW3-56 treatment (Fig. 4E). In contrast, a
decrease in PAD4 binding and histone H3 citrullination
(H3Cit) at the 733 position was detected after YW3-56 treat-
ment (Fig. 4E). The above results support a model in which
PAD4 serves as a corepressor of p53 to repress SESN2 expres-
sion in untreated cells. In contrast, after YW3-56 treatment,
p53 associates, whereas PAD4 dissociates from, the SESN2
FIGURE 2. Subcellular localization of YW3-56 and its inhibition of PAD4
and PAD2 activity. A, upon the addition of YW3-56 to U2OS cells, the subcel-
lular localization of YW3-56 (green color) was visualized by fluorescent micro-
scope. B, comparison of the GST-PAD4 and GST-PAD2 activity using histone
H3 substrate in Western blot (WB) experiments. C, different amounts of
YW3-56 were preincubated with PAD2 and PAD4. Enzymatic activity toward
histone H3 substrate after inhibitor incubation was detected by Western blot
experiments. The total amount of H3 was probed with a general histone H3
antibody. Representative results of over three repeats experiments are
shown in panels A–C.
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gene, allowing a decrease inH3Cit and an increase inH3R17Me
to activate SESN2 expression.
Role of SESN2 in YW3-56-mediated Inhibition of the
mTORC1 Signaling—SESN2 is induced by starvation and stress
conditions and serves as an upstream inhibitor of mTORC1 by
forming a complex with TSC1/2 (33). mTORC1 inhibition
decreases its phosphorylation of p70S6K and 4E-BP1, thereby
inhibiting translation, cell growth, and proliferation, whereas
accelerating autophagy (17, 18) (illustrated in Fig. 5A). Next, we
analyzed whether YW3-56 inhibits themTORC1 signaling cas-
cade by SESN2 induction. The amount of SESN2 protein was
increased by YW3-56 in U2OS cells treated with control
shRNA (Fig. 5B, lanes 1–4). In contrast, depletion of p53 by
shRNA decreased the basal level of SESN2 and its induced lev-
els after YW3-56 treatment (Fig. 5B, lanes 5–8), indicating that
p53 is important for the relative levels of SESN2 expression. It is
noteworthy that SESN2 expression can be induced at higher
YW3-56 concentrations (Fig. 5B, lane 8), suggesting that a low
level of p53 in p53-depleted U2OS cells is sufficient for YW3-
56-mediated SESN2 induction. Although the amount of
p70S6K protein was not altered in U2OS cells treated with
YW3-56 at different concentrations (Fig. 5B, lanes 1–4), the
depletion of p53 decreased the amount of p70S6K protein
regardless of inhibitor treatment (Fig. 5B, lanes 5–8). In agree-
ment with the inhibitory role of SESN2 in the SESN2-TSC1/2-
mTORC1 signaling axis, the induction of SESN2 by YW3-56
occurred with a concomitant decrease in p70S6K phosphory-
lation at Thr-389 (Fig. 5B). Furthermore, the inhibitory effects
of YW3-56 on histone H3 citrullination were detected in U2OS
cells treated with the control or the p53 shRNA (Fig. 5B).
To test whether YW3-56 induces SESN2 and inhibits mTOR
under stress conditions, we treated serum-starved U2OS cells
with YW3-56 or a combination of YW3-56 and serum. Under
serum starvation and serum stimulation conditions, YW3-56
treatment induced SESN2 expression and dramatically
decreased the phosphorylation of p70S6K as well as another
mTORC1 target protein 4E-BP1 (Fig. 5C). The phosphoryla-
tion of 4E-BP1 plays an important role in translation by regu-
lating its binding to the translation initiation factor eIF-4E (40,
51). To further assess the role of SESN2 in YW3-56-mediated
mTORC1 inhibition, we used siRNAs to deplete SESN2 in
U2OS cells. Depletion of SESN2 slightly increased p70S6K pro-
tein levels but drastically increased its phosphorylation levels
(Fig. 5D, lane 3 as compared with lane 1), suggesting that
SESN2 is important for regulating p70S6K phosphorylation in
cells without YW3-56 treatment. On the other hand, YW3-56
dramatically decreased p70S6K phosphorylation in cells
treated with the control GFP siRNA (Fig. 5D, lane 2 as com-
FIGURE 3. Cellular functions of genes affected by YW3-56 treatment. A, genes with changed expression after 8 M YW3-56 treatment for 8 h were analyzed
according to their gene ontology categories. Gene ontology terms are shown on the x axis together with the number of genes changed/the number of genes
with that category shown in parentheses. The scale for the log10 p values for the enrichment significance is graphed along the left side of the y axis, and the scale
for the percentages of genes showing changes within each category is graphed along the right side of the y axis. B, heat map of genes showing 2-fold
increased expression from three independent experiments (left columns) and genes showing 2-fold decreased expression from three independent experi-
ments (right columns). Each column represents an independent experiment. Yellow color indicates genes of increased expression, whereas blue color indicates
genes of decreased expression after YW3-56 treatment. FDR, false discovery rate. Ctrl, control.
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pared with lane 1), whereas p70S6K phosphorylation was only
slightly decreased after YW3-56 treatment in SESN2 depletion
cells (Fig. 5D, lane 4 as compared with lane 3), suggesting that
SESN2 is important for YW3-56-mediated inhibition of
p70S6K phosphorylation. Taken together, the above results
indicate that YW3-56 treatment can induce the expression of
SESN2, which in turn triggers a cascade of signaling events to
inhibit the mTORC1 kinase activity.
YW3-56 Regulates the Autophagy Flux—The induction of
upstream inhibitors of the mTORC1 pathway, which keeps the
Yin-Yang balance of translation and autophagy, prompted us to
analyze whether YW3-56 treatment regulates autophagy in
U2OS cells. In transmission electron microscopy (TEM) anal-
yses, many large vesicles containing engulfed and digested
membrane and organelle structures were observed in YW3-56-
treated cells but not in control cells (Fig. 6A and supplemental
Fig. S8). These large vesicular structures (denoted by red
arrows) have structural characteristics of autophagic vesicles
(e.g. autophagosomes and autophagolysosomes) (52). The for-
mation of phagophores and autophagosomes is associated with
lipidation of LC3-I with phosphatidylethanolamine to produce
the membrane-associated LC3-II protein (52). Consistent with
autophagic vesicle accumulation, LC3-II accumulated after
YW3-56 treatment in a drug dose-dependent manner (Fig. 6B).
Furthermore, LC3 stainingwas detected inmultiple large punc-
tate structures inU2OS cells after YW3-56 treatment but not in
control cells (Fig. 6C), offering additional evidence for the for-
mation of autophagosomes and/or autophagolysosomes after
YW3-56 treatment.
The flux rate of autophagy can be controlled by several steps:
1) the enclosure of cytoplasmic components by phagophores to
form autophagosomes; 2) the fusion of autophagosomes with
lysosomes to form autophagolysosomes; 3) the dissolution of
autophagolysosomes (illustrated in Fig. 6D). To analyze how
YW3-56 affects the stepwise progression of autophagy, we per-
formed live cell imaging using an mCherry-GFP-LC3 reporter
construct. The GFP signal in the mCherry-GFP-LC3 fusion
protein is quenched under acidic pH in autophagolysosomes,
FIGURE 4. Direct regulation of the SESN2 expression by p53 and PAD4. A, RT-qPCR analyses of p53 and its target gene expression after 6 h of YW3-56
treatment of U2OS cells with or without p53 depletion by shRNA. The expression levels of each gene in control U2OS cells without p53 depletion and YW3-56
treatment were normalized to 1. Averages and standard deviations are shown (n  3). B, representative Western blot results of the effects of YW3-56 on histone
H3 citrullination and SESN2 expression in U2OS cells with or without PAD4 siRNA treatment. C, schematic illustration of the SESN2 gene intron and exon
structure organization. Coordinates of the primers used to probe for p53 and PAD4 binding are indicated. TSS position is set as 1. D, ChIP analyses of p53
binding at the SESN2 gene before and after UV irradiation treatment for 6 h. E, ChIP analyses of p53 and PAD4 association as well as histone H3R17Me and H3Cit
modifications at the 733 position of SESN2 gene before and after YW3-56 treatment at 6 M for 6 h. Averages and standard deviations (n  2  3) are shown
(* indicates p  0.005). TSS, transcription start site.
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making it a nice fluorescent sensor to simultaneously analyze
autophagosomes and autophagolysosomes (52, 53). We found
that ectopically expressed mCherry-GFP-LC3 was detected as
predominantly red and dynamically moving spots with yellow
spots occasionally observed in control U2OS cells, suggesting
that the reporter protein was mainly associated with
autophagolysosomes (Fig. 6E and supplemental Video S1). In
contrast, after treatmentwith YW3-56, enlarged red and yellow
speckles with reduced movement were observed in cells
remaining attached to the culture surface (Fig. 6F and supple-
mental Video S2) and in moribund cells that were shrinking in
size and partially losing their attachment with the culture sur-
face (Fig. 6G and supplemental Video S3), indicating that both
autophagosomes and autophagolysosomes were accumulated
after YW3-56 treatment. Due to its selective degradation dur-
ing autophagy, p62 (also called sequestosome 1, SQSTM1)
serves as a marker for autophagy, and its cellular level inversely
correlates with the rate of autophagic vesicle degradation (52).
We found that p62 dramatically accumulated in YW3-56-
treated cells in a dose-dependent manner (Fig. 6B), suggesting
that YW3-56 regulates the autophagy flux by inhibiting
autophagic vesicle breakdown by lysosomes. Two scenarios
may lead to the accumulation of autophagic vesicles: first, an
increase in the influx rate with more autophagosome feeding
into the autophagy process; and second, a decrease in the efflux
rate with the less efficient fusion of autophagosomes with lyso-
somes and subsequent autophagolysosome dissolution. Note
that these two possible mechanisms are not mutually exclusive
and can function independently or in combination. Our results
suggest that YW3-56may induce the accumulation of autopha-
gosomes by inhibiting mTORC1 as well as inhibiting autopha-
gosome degradation to slow down the autophagy flux rate.
YW3-56 Effectively Inhibits Cancer Growth in Mouse Sar-
coma S-180XenograftModel—To test the effects of YW3-56 on
tumor growth in mice, we applied a well established mouse
sarcoma S-180 cell-derived tumor model (54). MTT assays
showed that YW3-56 inhibited S-180 cell growth with an IC50
of 10–15 M (Fig. 7A). RT-qPCR analyses showed that
YW3-56 treatment induced the expression of p53 and its target
genes, including SESN2, in a concentration-dependent manner
(Fig. 7B). Upon intraperitoneal injection of YW3-56 at a con-
centration of 10 mg/kg of mouse body weight daily for 1 week,
the growth of S-180 tumor was decreased to 51.5% of that of
the control group injected with an isotonic saline solution (Fig.
7,C andD). TheHDAC inhibitor SAHA (also called vorinostat)
is a United States Food and Drug Administration-approved
drug for treatment of cutaneous T cell lymphoma. As a refer-
ence to evaluate the effect of YW3-56, we injected SAHA at 5
FIGURE 5. YW3-56 regulates the mTOR signaling pathway through SESN2 induction. A, illustration of the p53-SESN2-mTORC1 signaling pathway. SESN2
forms complex with TSC1/2 to inhibit the mTORC1 activity and subsequent p70S6K phosphorylation, which offers a molecular mechanism linking YW3-56
treatment to autophagy regulation. B, the levels of p53, PAD4, SESN2, and p70S6K proteins, the phosphorylation of p70S6K at Thr-389, and the citrullination of
histone H3 were analyzed by Western blot experiments in U2OS cells treated with different doses of YW3-56 for 8 h. p53 was depleted by shRNA to analyze its
effects on cellular response to YW3-56 treatment. Actin was probed to ensure equal protein loading. The amount of histones in each lane was monitored by
Ponceau S staining for equal loading. C, Western blot analyses were performed to analyze SESN2, p70S6K, p70S6K Thr-389 phosphorylation, 4E-BP1, and 4E-BP1
Ser-65 phosphorylation after YW3-56 treatment for 8 h in U2OS cells with or without serum starvation. Actin was probed to ensure equal protein loading.
D, Western blot analyses were performed to analyze the effects of SESN2 depletion on p70S6K phosphorylation in U2OS cells without or with YW3-56 treatment
for 8 h. Representative results of over three repeats experiments are shown in panels B–D. Ctrl, Control.
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mg/kg of body weight concentration daily for 1 week and found
that S-180-derived tumor growth was decreased to 44.6% of
that of the control group (Fig. 7, C and D). As such, YW3-56
showed a similar tumor growth inhibition effect as that of
SAHA under the conditions applied. Additionally, because we
have found that PAD4 coordinates with HDAC2 in repressing
p53 target gene expression (25), we tested the synergy of the
PAD4 inhibitor and HDAC inhibitor in tumor growth. We
found that after injection of a mix of YW3-56 and SAHA at half
of their concentrations when applied singularly, tumor growth
was decreased to 27.1% of that of the control group (Fig. 7, C
and D), suggesting an additive effect of the two inhibitors. In
comparison with doxorubicin, a well established chemothera-
peutic reagent, amixture of YW3-56 and SAHA showed cancer
growth inhibition effect close to that of doxorubicin applied at
2 mg/kg of body weight concentration (Fig. 7, C and D).
To evaluate whether YW3-56 has adverse effects on the
growth and the vital organ functions in mouse, we measured
the body as well as brain, heart, liver, kidney, and spleen weight
after drug treatment. Daily injection of YW3-56 at 10 mg/kg of
body weight for 1 week did not decrease the size of mouse body
or organs, suggesting that the adverse effects of YW3-56 are low
if any (supplemental Fig. S9). Moreover, SAHA alone or
YW3-56 and SAHA in combination did not impair mouse
growth or sizes of vital organs (supplemental Fig. S9). In con-
trast, the size of the spleen was decreased to 50% of that of
control mice after doxorubicin treatment (supplemental Fig.
S9), suggesting that inhibitors targeting PAD4 and HDACs are
less toxic when compared with doxorubicin. Additionally, we
performed a 3-month YW3-56 treatment experiment with a
daily injection of YW3-56 at 10 mg/kg of body weight in a pair
of nude mice and determined that the sizes of the mouse body
and vital organs were not altered after YW3-56 treatment.
DISCUSSION
An emerging theme in the field of cancer research is that the
epigenetic silencing of tumor suppressor genes can lead to
increased cell growth and cell division during tumorigenesis.
Because epigenetic alterations do not include mutations in
DNA per se, tumor suppressor genes can be turned back on by
FIGURE 6. YW3-56 induces autophagy in human osteosarcoma U2OS cells. A, transmission electron microscopy images of mock-treated cells at low
magnification (Low mag.) and high magnification (High mag.) (upper panels) as well as YW3-56-treated cells (lower panels). Distinctive structures with charac-
teristics of autophagolysosomes in YW3-56-treated cells are denoted by red arrows. Scale bars are 1 m. B, levels of LC3-I and LC3-II as well as p62/SQSTM1 were
analyzed by Western blot after different doses of YW3-56 treatment for 12 h. C, LC3 was detected in large speckles denoted by white arrows in U2OS cells after
YW3-56 treatment cells (lower panels) but not in control cells (upper panels). D, schematic drawing of the autophagy process. The mCherry-GFP-LC3-PE reporter
is red and green when it associates with phagophores (also called isolation membranes) and autophagosomes (PE denotes phosphatidylethanolamine). After
fusion with lysosomes to form autophagolysosomes, the GFP signal is quenched by the acidic condition. E, a representative microscopy image showing
red-colored autophagolysosomes and red and green double-colored autophagosomes in control mock-treated cells. See video S1 for more details. F, a repre-
sentative microscopy image showing red-colored autophagolysosomes and red and green double-colored autophagosomes in YW3-56-treated cells with slight
morphology changes. See video S2 for more details. G, a representative microscopy image showing red-colored autophagolysosomes and red and green
double-colored autophagosomes in a moribund cell after YW3-56 treatment. Insets show details of the structures at higher magnification. See video S3 for more
details. Arrowheads denote autophagolysosomes, and arrows denote autophagosomes (E–G). Scale bars in panels E–G represent 5 m.
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targeting epigenetic modifiers, as evidenced by recent progres-
sion in this area (3–5). Previous pathological and genetic stud-
ies have linked PAD4 and protein Arg citrullination with sev-
eral human diseases, including cancers and autoimmune
disorders. In cancer cells, a fine-tuned increase of PAD4protein
represses the expression of p53 target genes, such as p21/
CDKN1A, GADD45, and PUMA. Here, using the newly devel-
oped PAD inhibitors, we identified a novel molecular mecha-
nism by which PAD4 represses the expression of the p53 target
gene SESN2 to promote cancer cell growth, suggesting that
PAD4 may facilitate tumorigenesis from multiple aspects. The
lead compound YW3-56 demonstrates tumor growth inhibi-
tion effects singularly or in combinationwith SAHA, whereas it
has little if any detectable side effects under the conditions
applied. Given that PAD4 is overexpressed in the majority of
human cancers of many tissue origins and that its levels are
elevated in the blood of cancer patients (21), further investiga-
tion of PAD4 and its inhibitors is of important value in cancer
diagnosis and treatment.
Cancer cells respond very fast to YW3-56 treatment. As
quick as 6 h after YW3-56 addition to U2OS cells, we observed
changes in cell morphology, such as a loss of cell attachment
and formation of cytosolic bubbles. This fast kinetics is in
agreement with the high membrane permeability and accumu-
lation in cancer cells detected by flow cytometry analyses as
well as the immediate induction of the SESN2 andDDIT4 gene
expression within hours after the drug treatment. Autophagy
represents an important cellular adaptation response to various
stress signals (37, 38, 52). Starvation leads to the activation of
several signaling pathways including the p53-SESN2 axis. Once
expressed, SESN2 canwork together with the TSC1-TSC2 pro-
tein complex to inhibit the mTORC1 complex-mediated phos-
phorylation of its target proteins that are involved in protein
synthesis. The decreased rate of protein translation is coupled
with a concomitant increase of cellular autophagy. Our siRNA
results showed that SESN2 is directly regulated by PAD4 and is
a sufficient factor for regulating the phosphorylation of
mTORC1 substrate p70S6K. YW3-56 activates the expression
of SESN2 and inhibits the phosphorylation of p70S6K, offering
a mechanism by which YW3-56 may induce autophagy. More-
over, YW3-56 treatment leads to the accumulation of both
autophagosomes and autophagolysosomes as well as the accu-
FIGURE 7. YW3-56 inhibits tumor growth in a mouse tumor model and cooperates with the HDAC inhibitor SAHA. A, the growth inhibition of mouse
sarcoma S-180 cells after YW3-56 treatment was analyzed by MTT assays (averages and standard deviations are shown, n  3). B, p53 and its target gene
expression levels were analyzed by RT-qPCR in S-180 cells after YW3-56 treatment (averages and standard deviations are shown, n  3). DRAM, damage-
regulated autophagy modulator; AMPK, AMP-activated protein kinase. C, growth inhibition of S-180 cell-derived tumors in mice by YW3-56, SAHA, a combi-
nation of YW3-56 and SAHA, or doxorubicin. In total, 27 mice for control, 21 mice for YW3-56, 11 mice for SAHA, 11 mice for SAHA and YW3-56, and 15 mice for
doxorubicin treatment from the above two independent experiments were used to collect data for tumor sizes and body/organ weights. Averages and
standard deviations are shown. Statistical analyses were performed using Student’s t test. D, representative images showing the tumor mass in control mice
and mice after YW3-56, SAHA, or a combination of YW3-56 and SAHA treatment.
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mulation of p62/SQSTM1, suggesting that it exacerbates the
autophagy burden by inhibiting autophagic vesicle degrada-
tion. Our ongoing research will further unveil the molecular
and cellular mechanisms underlying the YW3-56 activity to
curb cancer cell growth.
Cl-amidine was originally designed as a structural mimic
of the PAD substrate peptidylarginine by the Thompson
group (44). Cl-amidine shows a broad inhibition of all
active PAD family members, albeit at different efficiency
(PAD1PAD4PAD3PAD2) (45). Our work has found that
Cl-amidine exerts 50% tumor growth inhibition at 150–200
M concentrations (24). In this study, we developed a set of
novel PAD inhibitors by an extensive structure-and-activity
relationship study based on the chloroacetamidine functional
group, which covalently modifies the active center cysteine of
the PAD enzymes (44). The lead compound YW3-56 inhibits
cancer cell growth at low micromolar concentrations, showing
60-fold increase in cancer growth inhibition over Cl-amidine.
This gain in YW3-56 inhibitor efficacy is due to two possible
factors: 1) a mild increase in PAD4 inhibition achieved by opti-
mizing the backbone; and 2) a large increase in the membrane
permeability of YW3-56 by the addition of amore hydrophobic
dimethyl-amide-naphthalene moiety at the N position and a
phenyl ring at the C position. In parallel to our study, the
Thompson group (45, 55) has recently reported two additional
structures related to Cl-amidine by adding one or two amino
acids to theN position of Cl-amidine. Given that these inhib-
itors are all developed on amechanism-based design, they need
to compete with the in vivo PAD substrates to achieve efficient
inhibition. Allosteric effect inhibition may represent a future
strategy to develop additional inhibitors.On the other hand, the
current experimental data found that mechanism-based PAD
inhibitors derived from the Cl-amidine backbone show phar-
macological efficacy both in cell culture and in mouse models,
suggesting that this strategy may prove to be viable in future
pharmacology exploration.
The PAD family of contains five members in human and
mouse, including PAD1–4 and PAD6, that show tissue and
substrate specificity (56, 57). A recent study with PAD2, PAD3,
and PAD4 enzymes found that PAD4 prefers histone H3,
whereas PAD2 prefers actin for citrullination (11). However,
the interaction of PAD4 with its substrate peptides is mainly
mediated by the peptide backbone (58), suggesting that PAD4
may target Arg residues embedded in a diverse range of sub-
strates. To date, histones H3, H4, andH2A, ING4, nucleophos-
min, and nuclear lamin C have been identified as substrate of
PAD4. This imposes a future challenge in addressing the func-
tion of PAD4 in targeting these particular substrates. On the
other hand, the loose substrate context dependence of PAD
proteins likely imposes additional challenges to developing iso-
form-specific PAD inhibitors for biology and preclinical stud-
ies. The lead compound YW3-56 can inhibit both PAD2 and
PAD4. At the current stage of our inhibitor and drug develop-
ment, the broad inhibition of YW3-56 to PAD enzymes should
not be a concern for clinical application given that many effec-
tive cancer therapies target general cellular processes and suc-
cessful epigenetic inhibitors used in cancer therapy often target
a family of enzymes, such as the DNAmethyltransferase inhib-
itors and the histone deacetylase inhibitors.
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Addendum—In the first paragraph under “Experimental Proce-
dures” of the online published manuscript, we cited Ref. 44 (Luo et
al., Biochemistry, 2006), the original paper that developed the syn-
thesis method of Cl-amidine by Dr. Thompson’s group. However,
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